WO2021040042A1 - 特定の遺伝子マーカーを有する患者に用いるがん治療用の医薬組成物 - Google Patents
特定の遺伝子マーカーを有する患者に用いるがん治療用の医薬組成物 Download PDFInfo
- Publication number
- WO2021040042A1 WO2021040042A1 PCT/JP2020/032828 JP2020032828W WO2021040042A1 WO 2021040042 A1 WO2021040042 A1 WO 2021040042A1 JP 2020032828 W JP2020032828 W JP 2020032828W WO 2021040042 A1 WO2021040042 A1 WO 2021040042A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- pharmaceutical composition
- nat2
- administered
- subject
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 67
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 64
- 201000011510 cancer Diseases 0.000 title claims abstract description 57
- 108090000623 proteins and genes Proteins 0.000 title description 10
- 239000003550 marker Substances 0.000 title description 3
- 101150019103 NAT2 gene Proteins 0.000 claims abstract description 54
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- 101000884399 Homo sapiens Arylamine N-acetyltransferase 2 Proteins 0.000 claims description 94
- -1 5-amino-2-phenylbenzoxazole-7-yl Chemical group 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 20
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 18
- 201000009036 biliary tract cancer Diseases 0.000 claims description 17
- 238000003745 diagnosis Methods 0.000 claims description 14
- 230000002068 genetic effect Effects 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 13
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 10
- 201000002528 pancreatic cancer Diseases 0.000 claims description 10
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 10
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 9
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 9
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 9
- 229910052796 boron Inorganic materials 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 201000004101 esophageal cancer Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 210000003734 kidney Anatomy 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000009007 Diagnostic Kit Methods 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 229960005489 paracetamol Drugs 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000037819 metastatic cancer Diseases 0.000 claims description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000006134 tongue cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 101000713305 Homo sapiens Sodium-coupled neutral amino acid transporter 1 Proteins 0.000 claims 3
- 102100026783 N-alpha-acetyltransferase 16, NatA auxiliary subunit Human genes 0.000 claims 3
- 102100038110 Arylamine N-acetyltransferase 2 Human genes 0.000 description 91
- XNRZJPQTMQZBCE-SFHVURJKSA-N (2s)-2-amino-3-[4-[(5-amino-2-phenyl-1,3-benzoxazol-7-yl)methoxy]-3,5-dichlorophenyl]propanoic acid Chemical compound ClC1=CC(C[C@H](N)C(O)=O)=CC(Cl)=C1OCC1=CC(N)=CC2=C1OC(C=1C=CC=CC=1)=N2 XNRZJPQTMQZBCE-SFHVURJKSA-N 0.000 description 70
- 210000004027 cell Anatomy 0.000 description 29
- ZZYZBZJDTUKBBE-FQEVSTJZSA-N (2S)-3-[4-[(5-acetamido-2-phenyl-1,3-benzoxazol-7-yl)methoxy]-3,5-dichlorophenyl]-2-aminopropanoic acid Chemical compound CC(=O)Nc1cc(COc2c(Cl)cc(C[C@H](N)C(O)=O)cc2Cl)c2oc(nc2c1)-c1ccccc1 ZZYZBZJDTUKBBE-FQEVSTJZSA-N 0.000 description 28
- 239000008280 blood Substances 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 23
- 238000006640 acetylation reaction Methods 0.000 description 19
- 230000021736 acetylation Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 229920000858 Cyclodextrin Polymers 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 238000001990 intravenous administration Methods 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 11
- 102000054766 genetic haplotypes Human genes 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 102100038204 Large neutral amino acids transporter small subunit 1 Human genes 0.000 description 9
- 108091006232 SLC7A5 Proteins 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 206010071602 Genetic polymorphism Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 4
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 102000007990 Organic Anion Transporters Human genes 0.000 description 4
- 108010089503 Organic Anion Transporters Proteins 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 4
- 150000004982 aromatic amines Chemical class 0.000 description 4
- 229940097362 cyclodextrins Drugs 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 102200094927 rs1799931 Human genes 0.000 description 4
- 102200094889 rs1801280 Human genes 0.000 description 4
- 208000037560 slow acetylation Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 239000003978 infusion fluid Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 230000002974 pharmacogenomic effect Effects 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 102220197630 rs1041983 Human genes 0.000 description 3
- 102200094879 rs1801279 Human genes 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000011255 standard chemotherapy Methods 0.000 description 3
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 3
- 229960001940 sulfasalazine Drugs 0.000 description 3
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 3
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 102100038235 Large neutral amino acids transporter small subunit 2 Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 108091006238 SLC7A8 Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000000397 acetylating effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000004252 chorionic villi Anatomy 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229960003350 isoniazid Drugs 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000009790 rate-determining step (RDS) Methods 0.000 description 2
- 102220000301 rs1208 Human genes 0.000 description 2
- 238000009094 second-line therapy Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 101150068332 KIT gene Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108091006731 SLCO1B1 Proteins 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 102100027233 Solute carrier organic anion transporter family member 1B1 Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- JVFGXECLSQXABC-UHFFFAOYSA-N ac1l3obq Chemical compound O1C(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(O)C2O)C(COCC(O)C)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC2C(O)C(O)C1OC2COCC(C)O JVFGXECLSQXABC-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- GTXJHJOCVPTNTP-MLJFYOOPSA-N dimethyl-α-cyclodextrin Chemical compound COC[C@H]([C@H]([C@@H]([C@H]1OC)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)O)O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)O)O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)O)O3)[C@H](O)[C@H]2OC)COC)O[C@@H]1O[C@H]1[C@H](O)[C@@H](OC)[C@@H]3O[C@@H]1COC GTXJHJOCVPTNTP-MLJFYOOPSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- VNDHXHMRJVTMTK-WZVRVNPQSA-H hexasodium 4-[[(1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecahydroxy-10-(hydroxymethyl)-15,20,25,30,35-pentakis(4-sulfonatobutoxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-5-yl]methoxy]butane-1-sulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]1[C@H](O)[C@H]2O VNDHXHMRJVTMTK-WZVRVNPQSA-H 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- BJHIKXHVCXFQLS-OTWZMJIISA-N keto-L-sorbose Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-OTWZMJIISA-N 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000023833 nerve sheath neoplasm Diseases 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 102200094900 rs1799930 Human genes 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000011333 second-line chemotherapy Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- QPPBRPIAZZHUNT-UHFFFAOYSA-N sulfamerazine Chemical compound CC1=CC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 QPPBRPIAZZHUNT-UHFFFAOYSA-N 0.000 description 1
- 229960002597 sulfamerazine Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention is O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine, or O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine, which is optimally used for patients with cancer and the like having a specific genetic marker.
- a pharmaceutical composition comprising the pharmaceutically acceptable salt thereof.
- the present invention relates to O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine, for patients with cancer and the like having a specific genetic marker.
- the present invention relates to a method for treating cancer or the like, which comprises administering a pharmaceutical composition containing the pharmaceutically acceptable salt thereof.
- N-Acetyltransferase 2 is an enzyme that transfers the acetyl group of acetyl-CoA to an aromatic amine or hydrazine-containing compound that serves as a substrate for this enzyme.
- NAT2 is encoded by the 870-bp gene (NAT2), and genetic polymorphisms of NAT2 are common in humans.
- NAT2 a type having a high acetylation rate (Rapid), an intermediate type (Intermediate), and a slow type (Slow) (SNP; single nucleotide polymorphism) (Pharmacogenomics). , Volume 13, pp. 31-41, 2012). These types can be identified by their genetic polymorphisms.
- NAT2 Genetic polymorphisms in NAT2 are known to modify both the efficacy and toxicity of numerous arylamine and hydrazine drugs and increase the risk for some arylamine carcinogen-related cancers.
- a drug called sulfasalazine (SSZ) is acetylated by NAT2, but it is known that side effects are often likely to occur in patients with slow acetylation (J Rheumatur. 2002, Dec; 29 (12). ): 2492-2499) (Genotyping the NAT2 gene followed by estimation of diplotype configuration before administration of SSZ is likely to reduce the frequency of adverse effects in Japanese patients with RA.http: //www.jrheum.org/content/29/ 12/2492).
- Typical genetic polymorphisms of NAT2 are (i) 191G> A (rs1801279), (ii) 282C> T (rs1041983), (iii) 341T> C (rs1801280), (iv) 481C> T (rs17929929). ), (V) 590G> A (rs179930), (vi) 803A> G (rs1208), (vi) 857G> A (rs1799931).
- the SNPs of (i), (iii), (v), (vi) and (vii) result in amino acid changes (ie, (i) 191G> A from arginine to glutamic acid, (iii) 341T.
- C is isoleucine to threonine
- 590G> A is arginine to glutamine
- 803A> G is lysine to arginine
- 857G> A is glycine to glutamic acid).
- biliary tract cancer has been on the rise in Japan in recent years. The death toll in 2016 was about 18,000, making it the seventh leading cause of cancer death.
- the treatment policy and the effect of chemotherapy differ depending on the site of occurrence.
- gemcitabine and cisplatin combination therapy is regarded as standard chemotherapy as chemotherapy.
- the recommended second-line therapy for biliary tract cancer patients for whom standard chemotherapy is ineffective has not been established, and the clinical need for chemotherapy as second-line therapy is high.
- JPH203 O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine (hereinafter sometimes referred to as "JPH203”) is L that is specifically expressed in cancer cells. Since it has a selective inhibitory effect on type-amino acid transporter 1 (LAT1), it is expected to be effective as a new antitumor agent (Patent Document 1). Currently, JPH203 is undergoing a domestic phase II study in biliary tract cancer patients by the applicant.
- the inventors are investigating a new second-line chemotherapy for patients with biliary tract cancer who are refractory to standard chemotherapy, and based on the results of pharmacokinetic parameter analysis obtained in a domestic phase I study of JPH203, the same administration per body surface area
- the present invention is O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine, or pharmaceutically acceptable, for use in the treatment of disease in a subject.
- a pharmaceutical composition comprising a salt thereof, which is administered to the subject having a Non-Rapid (Slow and / or Intermediate) type NAT2 gene.
- the present invention is also a method of treating a disease in a subject, after the subject has been identified as having a Non-Rapid (Slow and / or Intermediate) type NAT2 gene, followed by O- (5-amino-2-).
- a method of treatment comprising administering to the subject a pharmaceutical composition comprising phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine, or a pharmaceutically acceptable salt thereof.
- the present invention relates to O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L- for use in the manufacture of a medicament for the treatment of a disease in a subject.
- the subject is administered a pharmaceutical composition comprising -amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine or a pharmaceutically acceptable salt thereof.
- a pharmaceutical composition comprising -amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine or a pharmaceutically acceptable salt thereof. Provide said use.
- the present invention predicts whether O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine is effective for specific cancers and the like.
- the method is provided by determining whether or not the NAT2 gene of interest has a Non-Rapid (Slow and / or Intermediate) type NAT2 gene.
- the present invention also relates to O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine or pharmaceutically used to produce a pharmaceutical for the treatment of a specific disease.
- Permissible use of the salt wherein the NAT2 gene of interest has a Non-Rapid (Slow and / or Intermediate) type NAT2 gene prior to treatment with the drug for a particular disease.
- the above-mentioned use which comprises predicting whether O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine is effective in a subject of a specific disease. I will provide a.
- the present invention is used to diagnose whether O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine is effective in a particular disease.
- -Il) Provided is a pharmaceutical composition comprising methyl-3,5-dichloro-L-tyrosine or a pharmaceutically acceptable salt thereof.
- subject and “patient” are used interchangeably in the present invention and are preferably human.
- the pharmaceutical composition of the present invention makes it possible to provide a treatment for cancer or the like with enhanced drug safety and improved efficacy.
- Borylated phenylalanine (BPA) was added to pancreatic cancer-derived cells T3M4, and 10 ⁇ M JPH203 was added 15 minutes later to show the concentration of BPA contained in the cells.
- O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine JPH203
- the active ingredient of the present invention, O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine is a compound disclosed in Patent Document 1 and is currently applied for. Phase II trials by humans are underway.
- O- (5-Amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine (JPH203) is metabolized (acetylated) mainly by liver NAT2 after intravenous administration. It becomes an acetyl form (Nac-JPH203) and its physiological activity is greatly reduced (Drug Metab Phenylackinet. 2012; 27 (1): pp. 155-61).
- JPH203 can also be used as its pharmacologically acceptable salt.
- the amino group in the molecule forms a salt together with the acid.
- Such salts are not particularly limited, and examples thereof include salts with inorganic acids such as hydrochloric acid and sulfuric acid, and carboxylic acids. Of these, hydrochloride is preferred.
- compositions contain JPH203 or a pharmacologically acceptable salt thereof as an active ingredient.
- pharmaceutical additives may be included if necessary.
- the pharmaceutical composition of the present invention can be orally administered in the form of solid preparations or liquid preparations such as tablets, granules, fine granules, powders and capsules, jellies and syrups, or the pharmaceutical composition.
- the physical medicine may be administered parenterally in the form of an injection, a nasal preparation, a suppository, an inhalant, a transdermal preparation, or the like.
- the pharmaceutical composition of the present invention can be used as an anticancer agent or the like, it is preferably formulated as an injection.
- injections include those containing a pH adjuster and cyclodextrins in the active ingredient of the present invention.
- injections include intravenous, subcutaneous, intradermal, intramuscular injections, and intravenous drip infusions.
- Examples of the pH adjuster that can be blended in the injection of the present invention include alkali metal hydroxides such as sodium carbonate, potassium carbonate, sodium hydroxide and potassium hydroxide, sodium hydride and potassium hydride.
- alkali metal hydroxides such as sodium carbonate, potassium carbonate, sodium hydroxide and potassium hydroxide, sodium hydride and potassium hydride.
- Alkali metal hydrides, alkali metals, alkali earth metal carbonates and the like, and in particular, sodium hydroxide and sodium carbonate are preferable, and sodium hydroxide is more preferable.
- the injection can be appropriately adjusted to an appropriate pH by using a pH adjusting agent.
- the pH of the injection according to the present embodiment is preferably 3 to 6, more preferably 3 to 5, further preferably 3 to 4.5, and 3.5 to 4.5. It is particularly preferable to have.
- unmodified cyclodextrin examples include ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin and the like.
- modified cyclodextrin for example, dimethyl- ⁇ -cyclodextrin, dimethyl- ⁇ -cyclodextrin, dimethyl- ⁇ -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin, hydroxypropyl- ⁇ - Cyclodextrin, sulfobutyl ether- ⁇ -cyclodextrin, sulfobutyl ether- ⁇ -cyclodextrin, sulfobutyl ether- ⁇ -cyclodextrin, maltosyl- ⁇ -cyclodextrin and the like can be mentioned.
- Cyclodextrins may be used alone or in any combination of two or more. Cyclodextrins are hydroxypropyl- ⁇ from the viewpoint of reducing the number of insoluble fine particles formed even when dissolved in a non-strongly acidic aqueous solution and improving the resolubility of lyophilized preparations in a non-strongly acidic aqueous solution. -Cyclodextrin or sulfobutyl ether- ⁇ -cyclodextrin is preferable, and sulfobutyl ether- ⁇ -cyclodextrin is more preferable.
- the sulfobutyl ether cyclodextrin has a structure represented by the following formula 1, and the inside of the cyclic structure is highly hydrophobic. Therefore, it forms a complex with O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine, which is also highly hydrophobic, by hydrophobic interaction.
- the reference to "sulfobutyl ether cyclodextrin complex" in the present specification refers to the above-mentioned hydrophobic interaction.
- the active ingredient O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine is added to the sulfobutyl ether cyclodextrin complex (hereinafter, "JPH203-"). It may be used in an injection as (referred to as "SBECD").
- a buffer a suspending agent, a solubilizing agent, a stabilizer, an tonicity agent, a preservative and the like may be added to the injection according to the present invention.
- buffer examples include boric acid buffer, phosphoric acid buffer, citric acid buffer, acetic acid buffer, Tris buffer and the like.
- suspending agent examples include methyl cellulose, polysorbate 80, hydroxyethyl cellulose, gum arabic, tragant powder, sodium carboxymethyl cellulose, polyoxyethylene sorbitan monolaurate, poloxamer, hydroxypropyl methyl cellulose (HPMC), sodium alginate and the like. Can be mentioned.
- solubilizing agent examples include polyoxyethylene hydrogenated castor oil, polysorbate 80, nicotinamide, polyoxyethylene sorbitan monolaurate, macrogol, glycerin fatty acid ester, lipoaminoacid, polyethylene glycol and the like.
- Stabilizers include sodium sulfite, sodium metasulfite, etc.
- tonicity agents include glycerin, sodium chloride, etc.
- preservatives include methyl paraoxybenzoate, ethyl paraoxybenzoate, sorbin. Examples include acid.
- the pH of the lyophilized preparation when dissolved in water is preferably 3 to 6, more preferably 3 to 5, further preferably 3 to 4.5, and 3.5 to 4 It is particularly preferably .5.
- the lyophilized preparation can be produced by a conventionally known method for producing a lyophilized preparation. For example, after freezing at a temperature of ⁇ 25 ° C. or lower, the temperature rises until the temperature reaches room temperature while maintaining the degree of vacuum at about 20 Pa or lower. Examples thereof include a method of drying while warming.
- the injection according to the present invention may be a lyophilized preparation.
- a lyophilized preparation can be used as a time-dissolving injection by dissolving it in, for example, distilled water for injection, an infusion solution, an electrolytic solution, or two or more kinds of solvents at the time of use.
- the pharmaceutical composition of the present invention can be used for the treatment of specific diseases, and the target diseases include, for example, fibromas, lipomas, mucinomas, chondromas, osteomas, hemangiomas, vascular endothelial tumors, lymphomas.
- Cancer bladder cancer, kidney cancer, bile sac cancer, prostate cancer, uterine body cancer, cervical cancer, ovarian cancer, mesenteric tumor, head and neck cancer, adrenal cancer, gastrointestinal stroma Cancer tumors such as tumors, parasite cancer, biliary tract cancer, pancreatic cancer, liver cancer, skin cancer, chorionic villus cancer, head and neck cancer, metastatic cancer, and invasive cancer; and a mixture thereof Tumors, metastatic tumors, etc .;
- biliary tract cancer, colon cancer, pancreatic cancer, esophageal cancer, breast cancer, lung cancer, prostate cancer, bladder cancer, brain tumor, stomach cancer, liver cancer, skin cancer, chorionic villus cancer, renal cancer , Head and neck cancer, tongue cancer, metastatic cancer, invasive cancer and the like are preferable, and biliary tract cancer, colon cancer, pancreatic cancer, esophageal cancer, and breast cancer are further recommended.
- Dosing regimen The dosing regimen to which the pharmaceutical composition of the invention applies is the type, race, age, weight, gender and medical condition of the patient; the severity of the condition to be treated; the route of administration; and the patient's liver and kidneys. It is selected according to various factors including function. Physicians can easily determine and prescribe the effective amount of drug needed to prevent, prevent or stop the progression of the condition.
- the dose of the active ingredient can be appropriately selected according to the degree of symptoms, the age, sex, body weight, sensitivity difference, administration time, administration interval, etc. of the patient, and is effective and safe.
- 1 mg / m 2 to 60 mg / m 2 (body surface area) is exemplified once, preferably 12.5 mg / m 2 to 60 mg / m 2 , 12.5 mg / m 2 to 25 mg /. m 2 or 10mg / m 2 ⁇ 40mg / m 2 ( body surface area) is illustrated and, in particular 25 mg / m 2 is recommended.
- the dose may be reduced to 12.5 mg / m 2 or the like depending on the symptoms.
- the pharmaceutical composition is administered as one cycle with a certain period of drug holiday following continuous administration for a certain period of time.
- the pharmaceutical composition is administered as one cycle with a total of 14 days of drug suspension for 9 days following continuous administration for 5 days.
- -A certain amount of the pharmaceutical composition is continuously administered intravenously over a certain period of time.
- -100 mL of the pharmaceutical composition is administered intravenously over 90 minutes.
- the pharmaceutical composition of the present invention is highly effective when administered to a patient having a Non-Rapid (Slow and / or Intermediate) type NAT2 gene (that is, a type in which acetylation by NAT2 is slow). It becomes possible to play.
- the "Non-Rapid type NAT2 gene” refers to one of the three phenotypes of the NAT2 gene, which has a high acetylation rate (Rapid), an intermediate type (Intermediate), and a slow type (Slow). It means the phenotypes of intermediate type and slow type.
- a heteroconjugate with a mutated one of the haplotypes is classified as a fast type (Rapid) and an intermediate type with an intermediate acetylation rate (Intermediate), and all are homoconjugates of the mutant haplotype or two or more thereof.
- the combination of the above mutant haplotype heterozygotes is considered to be a slow acetylation type (Slow) (Pharmacogenemics, Vol. 13, pp. 31-41, 2012).
- the "NAT2 * 4" allele means a haplotype without SNP.
- the Rapid type includes "NAT2 * 11, NAT2 * 12, NAT2 * 13" that do not cause amino acid mutation, in addition to "NAT2 * 4". Patients with it are also classified as Rapid type.
- the phenotype of the NAT2 acetylator inferred by the two SNPs is determined by the analysis of the two SNPs: rs1041983 (282C> T) and rs1801280 (341T> C).
- the NAT2 acetylating factor phenotype inferred by the three SNPs is determined by analysis of the three SNPs: rs1799992 (481C> T), rs179939 (590G> A) and rs1799931 (857G> A).
- the four SNP-estimated NAT2 acetylator phenotypes are determined by analysis of the four SNPs: rs1801279 (191G> A), rs1801280 (341T> C), rs1799930 (590G> A), and rs1799931 (857G> A).
- JPH203 When JPH203 is acetylated by NAT2, its inhibitory activity on cancer cells decreases. However, if the patient predominantly has a NAT2 genotype that is less susceptible to acetylation, i.e., in the NAT2 gene of patients such as cancer, an intermediate type and a slow type of acetylation rate (Intermediate) When it has the Slow) phenotype (Non-Rapid type NAT2 gene), the acetylation rate of JPH203 is slowed down, so that it becomes difficult to be acetylated, and the activity of JPH203 continues for a long time.
- the analysis of NAT2 gene polymorphism in the present invention can be performed by a conventionally known method. For example, it can be performed by extracting DNA from the blood of a subject, processing the DNA by the microarray method, then reading the genotype and performing a test, and then performing data analysis.
- an example of administration of the pharmaceutical composition of the present invention to a cancer patient is appropriately used. It is done as follows.
- NAT2 gene polymorphisms are confirmed.
- a Non-Rapid type ie, determined to be an intermediate type of acetylation or a slow acetylation type.
- Intravenous continuous administration is administered as one cycle for a total of 14 days with a 9-day drug holiday following continuous administration for 5 days.
- O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro is determined by determining whether or not the patient has the Non-Rapid type NAT2 gene. It is possible to predict whether -L-tyrosine is effective for patients with specific diseases such as cancer.
- the administration method for the pharmaceutical composition of the present invention to a patient, it is possible to provide excellent treatment for a specific disease, particularly cancer, etc., in which the safety of the drug is enhanced and the efficacy of the effect is improved. It becomes possible to do.
- O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine or pharmaceutically used in combination with NAT2 genetic diagnosis Provided is a pharmaceutical composition containing an acceptable salt thereof.
- the pharmaceutical composition is used for the treatment of a specific disease, particularly cancer, the effect thereof can be enhanced.
- the NAT2 gene diagnosis tests the NAT2 gene polymorphism and determines whether or not it has the Non-Rapid type NAT2 gene.
- the NAT2 gene diagnosis can be performed by a conventionally known diagnostic method, for example, a NAT2 gene polymorphism analysis method described later.
- NAT2 genetic diagnosis can use the services of testing institutions such as companies that provide genetic testing and genetic diagnosis.
- the NAT2 gene diagnosis can be performed by the NAT2 gene diagnosis kit.
- the NAT2 gene diagnostic kit is a collection of sample collection instruments and reagents necessary for carrying out the NAT2 gene polymorphism analysis method described later. Reagents provided in the kit eg, PCR enzyme solution, a primer / probe, dH 2 O, positive control DNA, and controls diluted dedicated buffer, and the like.
- a pharmaceutical composition comprising O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine of the invention or a pharmaceutically acceptable salt thereof.
- the product is used in combination with NAT2 genetic diagnosis or a genetic diagnostic kit.
- a pharmaceutical composition comprising O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine of the present invention or a pharmaceutically acceptable salt thereof.
- an effective treatment method for a specific disease for example, cancer, by using the substance in combination with NAT2 gene diagnosis or a gene diagnosis kit.
- a pharmaceutical composition comprising O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine of the present invention or a pharmaceutically acceptable salt thereof is NAT2.
- O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine of the present invention or a pharmaceutically acceptable salt thereof is NAT2.
- it can be administered to subjects with cancer in the following administration regimens.
- the subject having the Non-Rapid (Slow and / or Intermediate) type NAT2 gene is identified and selected; (2) The pharmaceutical composition is administered to the subject identified as having a Non-Rapid (Slow and / or Intermediate) type NAT2 gene.
- a pharmaceutical composition comprising O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine of the present invention or a pharmaceutically acceptable salt thereof is NAT2. It can be used in combination with inhibitors to treat diseases such as cancer. Examples of NAT2 inhibitors include acetaminophen.
- JPH203 is rapidly N-acetylated by NAT2 in the hepatic cytosol to become Nac-JPH203, but Nac-JPH203 is known to have lower selectivity and activity for LAT1 than JPH203, and NAT2 When used in combination with an inhibitor, it suppresses the acetylation of JPH203 and maintains the effect of JPH203.
- O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine or a pharmaceutically acceptable salt thereof and the amount of NAT2 inhibitor used are effective.
- the amount is used and can be appropriately selected depending on the administration target, administration route, disease, combination and the like.
- the timing of administration of O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine or a pharmaceutically acceptable salt thereof and a NAT2 inhibitor is particularly limited. Instead, administer the O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine of the present invention or a pharmaceutically acceptable salt thereof and a NAT2 inhibitor. It may be administered to the subject at the same time or at different times.
- O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine or a pharmaceutically acceptable salt thereof in combination with a NAT2 inhibitor The amount can be reduced, the treatment period can be set longer, and a synergistic effect can be obtained.
- O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine or pharmacy of the present invention can be used in the treatment of cancer in combination with boron neutron capture therapy.
- Examples of the compound used for boron neutron capture therapy include borated amino acids, and in particular, borated phenylalanine (BPA) (trade name: borophalan B10) is recommended.
- BPA borated phenylalanine
- Boron neutron capture therapy uses borated amino acids in combination with neutron irradiation.
- a boried amino acid eg, borated phenylalanine BPA
- BPA is taken up by cancer cells through LAT1.
- LAT1 When a neutron beam is irradiated there, nuclear fission occurs in the cancer cell and cell destruction occurs.
- BPA is easily excreted from cancer cells through LAT1, a large dose of BPA is required.
- a large amount of BPA is administered, it is also taken up by normal cells. As a result, it affects surrounding normal cells, causes side effects, and also affects the kidneys of organs that metabolize and excrete.
- BPA is taken up into cells through LAT1 on the surface of cancer cells. As it is, BPA is also excreted extracellularly by LAT1.
- LAT1 By administering JPH203 after BPA is taken up by cancer cells and before it is excreted from cancer cells, LAT1 can be covered and BPA can be contained in cancer cells (BPA and JPH203 administration). Time difference is important). Therefore, cancer cells can be efficiently attacked even if the dose of BPA is small. That is, JPH203 is effective in containing BPA. Since Nac-JPH203 has a lower cell growth inhibitory effect than JPH203, it is considered that NAT2 non-Rapid type is more effective than NAT2 Rapid type.
- the current standard BPA administration method is intravenous drip infusion, which is administered at a rate of 200 mg / kg / h for 2 hours before neutron irradiation, and during irradiation, an amount of 100 mg / kg is adjusted to the irradiation end time. It is administered at a constant rate of about 100 mg / kg / h. Too much of the goal of keeping BPA in cancer cells at a high concentration increases the concentration of extracellular matrix and the effect on normal cells.
- the timing of administration of JPH203 is 100 to 200 mg / kg / h of BPA before neutron irradiation for 30 minutes to 1 hour, and then immediately intravenously of JPH203 at a rate of 10 to 25 mg / kg / h. Intravenous administration. The neutron beam is irradiated 15 to 30 minutes after the start of JPH203 administration.
- BPA is taken up into normal cells through LAT2 on the surface of normal cells when the local concentration is high, the uptake efficiency of LAT2 is lower than that of LAT1. Since JPH203 covers only LAT1, BPA in cancer cells continues to be contained at a sufficiently high concentration at the start of neutron irradiation.
- O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine of the present invention or a pharmaceutical composition containing the same is used in combination with boron neutron capture therapy, the following Administration regimen is recommended.
- a cancer patient is intravenously infused as BPA at a rate of 200 mg / kg per hour for 1 hour.
- administration of BPA was discontinued, immediate intravenous administration of JPH203 at 10 to 20 mg / kg / h was started, neutron irradiation was started 30 minutes later, and intravenous infusion of JPH203 was administered during irradiation. Continues until the end of irradiation.
- NAT2 gene polymorphism is applied to the combination of O- (5-amino-2-phenylbenzoxazole-7-yl) methyl-3,5-dichloro-L-tyrosine and boron neutron capture therapy of the present invention.
- a combination of mold measuring methods may be used.
- Such methods include the following medication regimens; (1) The subject having the Non-Rapid (Slow and / or Intermediate) type NAT2 gene is identified and selected; (2) The boron-containing compound is administered to the subject identified as having the Non-Rapid (Slow and / or Intermediate) type NAT2 gene prior to administration of the pharmaceutical composition; and (3) the pharmaceutical.
- the composition is administered to the subject.
- Example 1 Drugs used JPH203-SBECD (50 mg as an active ingredient) is dissolved in 9.7 ml of water for injection to a concentration of 50 mg / 10 ml, and finally the total amount is 100 ml according to the body surface area of the patient.
- the cycle of repeated administration of the investigational drug was continued from 7 days after the single administration to the discontinuation criteria for the subjects who received the single administration and judged that there was no problem in their health condition.
- the first subject had no safety problem 49.5 hours after the start of administration on the 7th day of cycle 1 the administration of the second and subsequent subjects was started.
- Intravenous continuous administration was received over 90 minutes via an infusion circuit containing a final filter (pore size 0.22 ⁇ m) and a metering pump.
- the subject was prepared with an appropriate infusion solution such as physiological saline and Ringer's solution once a day for 7 days at the same dosage and administration as in cycle 1 to obtain the desired concentration. Received administration.
- Plasma samples were collected from the subjects.
- the whole blood used for the concentration measurement was collected 0.5, 1, 1.5, 2, 3, 4.5, 6, 12, 25.5, 49.5 hours after the start of administration.
- the urine used for the concentration measurement was collected by collecting urine every 0-3, 3-6, 6-12, 12-25.5 hours from the start of administration.
- the JHP203 concentration in blood and urine and the Nac-JPH203 concentration, which is an acetyl form thereof, were measured using a validated LC-MS / MS measurement system.
- Pharmacokinetic parameters were calculated using blood JPH203 concentration and Nac-JPH203 concentration. Among them, AUC0- ⁇ was used to determine the ratio of Nac-JPH203 to JPH203 in the blood of each subject. In addition, the total mass of JPH203 and Nac-JPH203 contained in the urine collected from the start of administration to 25.5 hours was calculated for each subject, and the ratio of Nac-JPH203 to JPH203 in urine in each subject was determined.
- Measurement of NAT2 gene polymorphism can be carried out by either the following real-time PCR method or a method using the Luminex System. In either method, the following seven types of SNPs are analyzed for NAT2.
- Real-time PCR method Measure by the real-time PCR method according to the following method. The details of the protocol can be changed as appropriate.
- the PCR product is purified and measured by a capillary sequencer. PCR primers are used as sequencing primers, and sequencing is performed from both sides of the PCR product.
- NAT2 gene polymorphism was carried out as follows. DNA was extracted from the blood sample at the time of the phase I test, and Phenotypes were classified from the information of each SNP according to the gene polymorphism of NAT2. The outline of the method is as follows; DNA was extracted by eluting 200 ⁇ L of whole blood into 100 ⁇ L of AE buffer and then using QIAamp DNA Blood Mini kit (registered trademark) (Kiagen Co., Ltd.).
- Fluorescent probes are labeled with a reporter dye (carboxyfluorescein or VIC®, Applied Biosystems) and have seven NAT2SNPs (rs1801279 (191G> A), rs1041983 (282C> T), rs1801280 (341T> C), s1801280 (341T> C), r. It was made to react specifically with one of the two bases at 481C> T), rs17993930 (590G> A), rs1208 (803A> G) and rs1799931 (857G> A)). The PCR reaction conditions were 95 ° C. for 10 minutes, followed by 50 cycles of 92 ° C. for 15 seconds and 60 ° C. for 90 seconds.
- a reporter dye carboxyfluorescein or VIC®, Applied Biosystems
- NAT2 SNP phenotype classification by NAT2 genotyping The NAT2 SNP phenotypes of 16 subjects were 2-SNP, regardless of cancer type (colon cancer, biliary tract cancer, pancreatic cancer, esophageal cancer and breast cancer). The results were consistent with any combination of 3-SNP and 4-SNP. Table 3 shows the details of the results.
- PD Stable (tumor size does not change)
- Partial response (a state in which the sum of tumor sizes has increased by 20% or more and the absolute value has increased by 5 mm or more, or a new lesion has appeared)
- PAAD Pancreatic cancer (Pancreas Adenocarcinoma)
- CHOL Cholangiocarcinoma
- COAD Colon Adenocarcinoma
- BRCA Breast Cancer (Brest Adenocarcinoma)
- ESCA Esophageal Cancer (Esophageal Carcinoma)
- PFS progression-free survival
- OS overall survival
- JPH203 is taken up by the liver and metabolized. JPH203 taken up by the liver is acetylated and converted to N-acetyl-JPH203 (Nac-JPH203), and Nac-JPH203 is excreted to the outside depending on the blood flow velocity. Both JPH203 and Nac-JPH203 are taken up by hepatocytes by OATP (organic anion transporter), and excretion from hepatocytes is performed by Mrp2 (multidrug-resistant protein: multidrug response assisted protein 2).
- OATP organic anion transporter
- the rate-determining step of metabolism of JPH203 is the uptake process (rats), but in humans, it is related to the hepatic blood flow rate. There was a lot of retention in hepatocytes, and it was thought that intracellular metabolism (the process of acetylation by NAT2) after being taken up would be the rate-determining step.
- the NAT2 of the subjects who participated in the phase I study was analyzed by 7 SNPs, and the phenotype of each subject's NAT2 (acetylation rate: Rapid, Intermediate) was analyzed regardless of the combination of 2-SNPs, 3-SNPs, and 4-SNPs. , And Slow) showed consistent results (Table 3).
- NAT2 SNP analysis of NAT2 is useful as a "companion diagnostic" for identifying a target (patient with cancer, etc.) for which treatment of JPH203 is effective and maximizing its antitumor activity.
- the superiority of administration to patients having the Non-Rapid type NAT2 gene further indicates that the patients to be treated in advance are the group having the Non-Rapid type gene and the Rapid type. It can be confirmed by a randomized controlled trial in which the test is performed after classifying into the group having the gene.
- JPH203 was administered, for example, 25 mg / m 2 , 5 days continuous administration, 9 days withdrawal, and 14 days as a basic cycle, and the total amount (100 mL) of the investigational drug assigned to each subject was administered. ), Continuous intravenous administration over 90 minutes using a syringe pump or infusion pump.
- Data analysis methods include, for example, for progression-free survival based on a blinded independent central assessment, the NAT2 metabolic type (Rapid) in all subjects who received at least one investigational drug and had efficacy data.
- the hazard ratio and its 95% confidence interval for each population were calculated using the Cox proportional hazard model, and the interaction between the administration group and the NAT2 metabolism type.
- the p-value for the interaction term can be calculated by the Cox proportional hazard model including the term.
- the hazard ratio in each population (Rapid type, Non-Rapid type) and its 95% confidence interval are determined by using the Cox proportional hazard model for each metabolic type (Rapid type, Non-Rapid type) of NAT2.
- the p-value for the interaction term is calculated by a Cox proportional hazard model including the interaction term between the administration group and the NAT2 metabolism type.
- progression-free survival based on the evaluation of doctors, for each metabolic type (Rapid type, Non-Rapid type) of NAT2, for progression-free survival (PFS) based on the evaluation of the investigator (sharing) doctor, Cox proportional hazard.
- Example 2 Combination experiment of JPH203 and NAT2 inhibitor Whether administration of acetaminophen (APAP), which is a NAT2 inhibitor, increases the concentration of JPH203 in plasma and liver, or decreases the concentration of its metabolite, Nac-JPH203. To evaluate.
- APAP acetaminophen
- the animal used was a male SD rat 8 weeks old, and 1.20 nmol / (minute / kg) JPH203 was administered. Dilute to this concentration with saline and the dosing rate is 20 ⁇ L / min. 500,1500 mg / kg acetaminophen was administered 30 minutes prior to JPH203 administration. (0.5% aqueous methylcellulose solution).
- the time of blood collection was 0 (blank), 30, 60, 120, 180, 240 minutes after administration of JPH203.
- the amount of sample to be collected was 0.2 mL as plasma and about 0.4 mL as blood, and liver, kidney, brain and CSF were collected.
- Example 3 Pancreatic cancer-derived cell T3M4 was used as a representative cancer cell, BPA was added to the cell, and 10 ⁇ M JPH203 was added 15 minutes later, and the concentration of BPA contained in the cell was measured. The results are shown in FIG. When JPH203 is not added ( ⁇ ), the intracellular concentration of BPA decreases because it is excreted from the cells over time. On the other hand, in the case of addition of JPH203 ( ⁇ ), it can be seen that the intracellular concentration is maintained because the excretion of BPA is suppressed by JPH203, and the intracellular concentration of the two is about 10 times different after 30 minutes.
- the pharmaceutical composition of the present invention makes it possible to provide a treatment for cancer or the like with enhanced drug safety and improved efficacy.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Rheumatology (AREA)
Abstract
Description
本発明の有効成分であるO-(5-アミノ-2-フェニルベンズオキサゾール-7-イル)メチル-3,5-ジクロロ-L-チロシンは、特許文献1に開示された化合物であり、現在出願人らによる第II相試験が進行中のものである。
本発明の医薬組成物は、有効成分としてJPH203またはその薬理学的に許容される塩を含む。また、必要に応じて医薬品添加物を含んでもよい。本発明の医薬組成物は、錠剤、顆粒剤、細粒剤、粉剤、カプセル剤などの固形製剤または液剤、ゼリー剤、シロップ剤などの形態で、経口投与することができ、あるいは、該医薬組成物薬は、注射剤、経鼻剤、坐剤、吸入剤、経皮剤などの形態で、非経口的に投与してもよい。
本発明の医薬組成物が適用される投薬レジメは、患者のタイプ、人種、年齢、体重、性別および医学的状態;処置すべき状態の重症度;投与経路;ならびに患者の肝および腎機能をはじめとする様々な要因に従って選択される。医師は、その症状の進行を予防、阻止または停止させるために必要な薬物の有効量を容易に決定し、処方することができる。
-医薬組成物が、一定期間連続投与に続く一定期間の休薬を1サイクルとして投与される、
-医薬組成物が、5日間の連続投与に続く9日間の休薬の計14日を1サイクルとして投与される、
-一定量の医薬組成物が、一定時間かけて静脈内持続投与される、
-医薬組成物100mLが、90分かけて静脈内持続投与される、
-患者に対して1~60mg/m2で投与される、
-患者に対して12.5~60mg/m2で投与される、
-患者に対して12.5~25mg/m2で投与される、
-患者に対して25mg/m2で投与される、
等が挙げられ、必要に応じてこれらを組み合わせて適用可能である。
(2) Non-Rapid(Slow及び/またはIntermediate)型のNAT2遺伝子を有すると同定された当該対象に当該医薬組成物を投与する。
更に、本発明のO-(5-アミノ-2-フェニルベンズオキサゾール-7-イル)メチル-3,5-ジクロロ-L-チロシンまたは薬学的に許容されるその塩は、ホウ素中性子捕捉療法と併用して、がんの治療に用いることができる。
(1) Non-Rapid(Slow及び/またはIntermediate)型のNAT2遺伝子を有する前記対象を同定して選択し;
(2) 含ホウ素化合物を、当該医薬組成物を投与する前に、Non-Rapid(Slow及び/またはIntermediate)型のNAT2遺伝子を有すると同定された当該対象に投与し;そして
(3) 当該医薬組成物を、当該対象に投与する。
使用薬剤:JPH203-SBECD(有効成分として50mg)を注射用水9.7mlに溶解させ、50mg/10ml濃度とし、最終的に患者の体表面積に従い、全量100mlとする。
被験者から、血液(全血)及び尿を採取した。濃度測定に用いた全血は、投与開始から0.5、1、1.5、2、3、4.5、6、12、25.5、49.5時間後に採取した。濃度測定に用いた尿は、投与開始から0-3、3-6、6-12、12-25.5時間ごとに蓄尿で採取した。血中・尿中のJHP203濃度およびそのアセチル体であるNac-JPH203濃度を、バリデーションされたLC-MS/MSの測定系を用いて測定した。
NAT2遺伝子多型の測定は、以下のリアルタイムPCR法またはLuminex Systemを用いる方法のいずれかの方法で実施することができる。いずれの方法においても、NAT2に関して下記の7種類のSNPsを解析対象とする。
下記の方法に従いリアルタイムPCR法で測定する。なお、プロトコルの詳細については適宜変更することができる。
(i) NAT2のDNA濃度を測定した後、解析対象SNPs7種を含む領域を増幅できるForward Primer2種およびReverse Primer1種を設計する。
(ii) これらのPCRプライマーを用いてPCR条件を検討し、最終的に使用するPCRプライマーセットおよびPCR条件を決定する。その後、決定した条件により、ゲノムDNAについてサンガーシーケンス法による配列解析を実施する。
(iii) PCR後、PCR産物の精製およびキャピラリーシーケンサーによる測定を行う。シーケンスプライマーにはPCR プライマーを使用し、PCR 産物の両側よりシーケンスを実施する。
下記の方法に従いLuminex System法で測定する。なお、プロトコルの詳細については適宜変更も可能とする。
(i) NAT2の解析対象とする7SNPsに対応するプローブ固相ビーズを作成する。
(ii)ビオチン標識プライマーでNAT2遺伝子を増幅させる。このPCR増幅産物をプローブと結合させ、SA-PEで蛍光標識する。
(iii)Luminex Systemでデータを取得し、解析ソフトウェアでNAT2遺伝子のタイプを表示する。
NAT2遺伝子多型の検査は以下のように実施した。第I相試験時の血液サンプルからDNAを抽出し、NAT2の遺伝子多型に応じて、各SNPの情報からPhenotypeを分類した。方法の概要は以下のとおりである;
DNAの抽出は、全血200μLをAE buffer 100μLに溶出後、QIAamp DNA Blood Mini kit(登録商標)(株式会社キアゲン)を用いて行った。NAT2をコードする部位にあるSNPと関連するアレーおよびハプロタイプの測定には、超微量分光光度計(Nano Drop 2000(登録商標)、サーモフィッシャーサイエンティフィック)を用いた(濃度は5ng/μLに調整)。遺伝子多型解析はTaqMan(登録商標)SNP Genotyping assayを用いた(反応容量5μL)。SNPを検出するために必要なPCRプライマーと蛍光プローブはPrimer Express(商標)(Applied Biosystems,CA,USA)を用いてデザインした。蛍光プローブはリポーター色素(carboxyfluoresceinあるいはVIC(登録商標),Applied Biosystems)によってラベルしておき、7つのNAT2SNP(rs1801279(191G>A),rs1041983(282C>T),rs1801280(341T>C),rs1799929(481C>T),rs1799930(590G>A),rs1208(803A>G)およびrs1799931(857G>A))にある2つの塩基のうちの1つに特異的に反応するようにした。PCRの反応条件は、95℃で10分に続いて、92℃で15秒と60℃で90秒を50サイクル行った。
16例の被験者のNAT2 SNP表現型は、がん種(大腸がん、胆道がん、膵臓がん、食道がんおよび乳がん)にかかわらず、2-SNP、3-SNP、4-SNPのいずれの組み合わせでも一致した結果であった。表3にその結果の詳細を示す。
PD:部分奏効(腫瘍の大きさの和が20%以上増加かつ絶対値でも5mm以上増加した状態、あるいは新病変が出現した状態)
PAAD:膵がん(Pancreas Adenocarcinoma)
CHOL:胆道がん(Cholangiocarcinoma)
COAD:大腸がん(Colon Adenocarcinoma)
BRCA:乳がん(Breast Adenocarcinoma)
ESCA:食道がん(Esophageal Carcinoma)
16例の個体のNac-JPH203/JPH203濃度比のばらつきをNAT2のRapidタイプ、Intermediateタイプ、およびSlowタイプに分類してみると、代謝物Nac-JPH203が多いタイプはNAT2 Rapidタイプであり、逆に代謝物の少ない個体はNAT2 Slowタイプであった。これらNAT2 Rapid群のうちNac-JPH203比率の高い4例で肝機能検査値の上昇が認められ、うち2例はDLT(Dose Limiting Toxicity)と判断された。これらの患者は大腸がん2例、食道がん1例、すい臓がん1例であり、胆道がん患者は含まれなかった。
JPH203とNAT2阻害剤との併用実験
NAT2阻害剤であるアセトアミノフェン(APAP)投与により、血漿中、肝臓中のJPH203濃度が上昇するか、またその代謝物であるNac-JPH203濃度が低下するかを評価する。
代表的ながん細胞として膵がん由来細胞T3M4を用い、該細胞にBPAを添加し、15分後に10μM JPH203を添加し、細胞内に封じ込められたBPA濃度を測定した。結果を図2に示す。JPH203非添加(●)の場合、BPAは時間を追うごとに細胞から排出されるため細胞内濃度が減少する。一方でJPH203添加(■)の場合、JPH203によりBPAの排出が抑制されるため細胞内濃度が保たれ、30分後では両者の細胞内濃度は10倍程度の差がついていることがわかる。
Claims (20)
- 対象のがん疾患の治療に使用するための、O-(5-アミノ-2-フェニルベンズオキサゾール-7-イル)メチル-3,5-ジクロロ-L-チロシン、または薬学的に許容されるその塩を含む医薬組成物であって、Non-Rapid(Slow及び/またはIntermediate)型のNAT2遺伝子を有する前記対象に投与される医薬組成物。
- がん疾患が、胆道がん、大腸がん、膵臓がん、食道がん、乳がん、肺がん、前立腺がん、膀胱がん、脳腫瘍、胃がん、肝臓がん、皮膚がん、絨毛がん、腎がん、頭頚部がん、舌がん、転移性がん及び浸潤がんからなる群から選択される、請求項1に記載の医薬組成物。
- がん疾患が、胆道がん、大腸がん、膵臓がん、食道がん及び乳がんからなる群から選択される、請求項2に記載の医薬組成物。
- 医薬組成物が、一定期間連続投与に続く一定期間の休薬を1サイクルとして投与される、請求項1~3のいずれか一項に記載の医薬組成物。
- 医薬組成物が、5日間の連続投与に続く9日間の計14日の休薬を1サイクルとして投与される、請求項4に記載の医薬組成物。
- 医薬組成物が、1~60mg/m2で対象に投与される、請求項1~5のいずれか一項に記載の医薬組成物。
- 医薬組成物が、12.5~60mg/m2で対象に投与される、請求項6に記載の医薬組成物。
- 医薬組成物が、12.5~25mg/m2で対象に投与される、請求項7に記載の医薬組成物。
- 一定量の医薬組成物が、一定時間かけて静脈内持続投与される、請求項1~8のいずれか一項に記載の医薬組成物。
- 100mLの医薬組成物が、90分かけて静脈内持続投与される、請求項9に記載の医薬組成物。
- O-(5-アミノ-2-フェニルベンズオキサゾール-7-イル)メチル-3,5-ジクロロ-L-チロシンが特定のがん疾患に効果を奏するかどうかを診断または予測する方法であって、対象のNAT2遺伝子において、Non-Rapid型のNAT2遺伝子を有するかどうかを判定する工程を含む、診断または予測する方法。
- O-(5-アミノ-2-フェニルベンズオキサゾール-7-イル)メチル-3,5-ジクロロ-L-チロシンが特定のがん疾患に効果を奏するかどうかを診断ために、対象のNAT2遺伝子において、Non-Rapid型のNAT2遺伝子を有するかどうかを判定するための遺伝子診断キット。
- 請求項12に記載の遺伝子診断キットと組み合わせて用いる、O-(5-アミノ-2-フェニルベンズオキサゾール-7-イル)メチル-3,5-ジクロロ-L-チロシンまたは薬学的に許容されるその塩を含む医薬組成物。
- NAT2遺伝子診断と組み合わせて用いる、がん治療用のO-(5-アミノ-2-フェニルベンズオキサゾール-7-イル)メチル-3,5-ジクロロ-L-チロシンまたは薬学的に許容されるその塩を含む医薬組成物。
- 対象のがん疾患の治療に使用するための、O-(5-アミノ-2-フェニルベンズオキサゾール-7-イル)メチル-3,5-ジクロロ-L-チロシン、または薬学的に許容されるその塩を含む医薬組成物であって、NAT2阻害剤と組み合わせて用いる、医薬組成物。
- NAT2阻害剤がアセトアミノフェンである、請求項15に記載の医薬組成物。
- Rapid型のNAT2遺伝子を有する前記対象に投与される、請求項15に記載の医薬組成物。
- 対象におけるがんの治療に使用するための、O-(5-アミノ-2-フェニルベンズオキサゾール-7-イル)メチル-3,5-ジクロロ-L-チロシン、または薬学的に許容されるその塩を含む医薬組成物であって、下記レジメで投与されることを特徴とする、医薬組成物:
(1) Non-Rapid(Slow及び/またはIntermediate)型のNAT2遺伝子を有する前記対象を同定して選択し;
(2) 含ホウ素化合物を、当該医薬組成物を投与する前に、Non-Rapid(Slow及び/またはIntermediate)型のNAT2遺伝子を有すると同定された当該対象に投与し;そして
(3) 当該医薬組成物を、当該対象に投与する。 - 当該医薬組成物を投与後に、更に中性子捕捉療法(BNCT)によりがんを死滅させる、請求項1~10及び13~17のいずれか一項に記載の医薬組成物。
- 対象がヒトである、請求項1~10及び請求項13~19のいずれか一項に記載の医薬組成物、請求項11に記載の方法、または請求項12に記載のキット。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20856673.7A EP4023298A4 (en) | 2019-08-30 | 2020-08-31 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT IN PATIENTS WITH SPECIFIC GENE MARKER |
MX2022002312A MX2022002312A (es) | 2019-08-30 | 2020-08-31 | Composicion farmaceutica para tratar cancer utilizada para un paciente que tiene un marcador genetico especifico. |
US17/638,669 US20220288035A1 (en) | 2019-08-30 | 2020-08-31 | A pharmaceutical composition for treating cancer used for a patient having specific genetic marker |
BR112022003220A BR112022003220A2 (pt) | 2019-08-30 | 2020-08-31 | Uma composição farmacêutica para tratar câncer usada para um paciente tendo marcador genético específico |
KR1020227007268A KR20220054312A (ko) | 2019-08-30 | 2020-08-31 | 특정의 유전자 마커를 갖는 환자에게 사용하는 암 치료용의 의약 조성물 |
CA3152367A CA3152367A1 (en) | 2019-08-30 | 2020-08-31 | Pharmaceutical composition for cancer treatment in patient having specific gene marker |
CN202080062102.XA CN114364381A (zh) | 2019-08-30 | 2020-08-31 | 用于具有特定的基因标志的患者的癌症治疗用药物组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019158681 | 2019-08-30 | ||
JP2019-158681 | 2019-08-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021040042A1 true WO2021040042A1 (ja) | 2021-03-04 |
Family
ID=74684222
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/032829 WO2021040043A1 (ja) | 2019-08-30 | 2020-08-31 | 特定の遺伝子マーカーを有する患者に用いる医薬組成物 |
PCT/JP2020/032828 WO2021040042A1 (ja) | 2019-08-30 | 2020-08-31 | 特定の遺伝子マーカーを有する患者に用いるがん治療用の医薬組成物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/032829 WO2021040043A1 (ja) | 2019-08-30 | 2020-08-31 | 特定の遺伝子マーカーを有する患者に用いる医薬組成物 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20220288035A1 (ja) |
EP (2) | EP4023296A1 (ja) |
JP (3) | JP6894155B2 (ja) |
KR (2) | KR20220054312A (ja) |
CN (2) | CN114340621A (ja) |
BR (2) | BR112022002894A2 (ja) |
CA (2) | CA3152367A1 (ja) |
MX (2) | MX2022002316A (ja) |
TW (2) | TW202122080A (ja) |
WO (2) | WO2021040043A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020073586A (ja) * | 2017-12-28 | 2020-05-14 | ジェイファーマ株式会社 | がん治療薬 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110945361B (zh) * | 2017-11-07 | 2024-01-09 | J制药股份有限公司 | 抗pd-1/pd-l1抗体疗法显效性的预测和提高方法以及评价癌症恶性程度的方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007209286A (ja) * | 2006-02-10 | 2007-08-23 | Sutaagen:Kk | St合剤の副作用の危険性の判定方法 |
JP2007525214A (ja) * | 2004-01-30 | 2007-09-06 | ケムジェネックス・ファーマシューティカルズ・インコーポレイテッド | N−アセチルトランスフェラーゼ遺伝子型解析によって投与するナフタルイミド |
WO2008081537A1 (ja) | 2006-12-28 | 2008-07-10 | Human Cell Systems, Inc. | Lat1阻害活性を有する芳香族アミノ酸誘導体、それを含有するlat1阻害活性剤及びその製造方法 |
WO2017175827A1 (ja) * | 2016-04-08 | 2017-10-12 | 株式会社Cics | 合成アミノ酸の癌細胞内取り込みを保持する修飾法と正常細胞を保護する中性子捕捉療法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5470665B1 (ja) * | 2013-08-20 | 2014-04-16 | ジェイファーマ株式会社 | 免疫抑制剤 |
EP3860639B1 (en) * | 2018-10-02 | 2023-12-06 | Georgetown University | An inhibitor of slc7a5 or lat1 for use in promoting remyelination of neurons |
-
2020
- 2020-08-31 CA CA3152367A patent/CA3152367A1/en active Pending
- 2020-08-31 KR KR1020227007268A patent/KR20220054312A/ko unknown
- 2020-08-31 WO PCT/JP2020/032829 patent/WO2021040043A1/ja unknown
- 2020-08-31 EP EP20856366.8A patent/EP4023296A1/en not_active Withdrawn
- 2020-08-31 US US17/638,669 patent/US20220288035A1/en active Pending
- 2020-08-31 CN CN202080060943.7A patent/CN114340621A/zh active Pending
- 2020-08-31 US US17/638,680 patent/US20220288036A1/en active Pending
- 2020-08-31 MX MX2022002316A patent/MX2022002316A/es unknown
- 2020-08-31 CA CA3152369A patent/CA3152369A1/en active Pending
- 2020-08-31 MX MX2022002312A patent/MX2022002312A/es unknown
- 2020-08-31 CN CN202080062102.XA patent/CN114364381A/zh active Pending
- 2020-08-31 BR BR112022002894A patent/BR112022002894A2/pt not_active Application Discontinuation
- 2020-08-31 BR BR112022003220A patent/BR112022003220A2/pt unknown
- 2020-08-31 TW TW109129768A patent/TW202122080A/zh unknown
- 2020-08-31 JP JP2020145283A patent/JP6894155B2/ja active Active
- 2020-08-31 EP EP20856673.7A patent/EP4023298A4/en active Pending
- 2020-08-31 KR KR1020227007270A patent/KR20220054603A/ko unknown
- 2020-08-31 TW TW109129769A patent/TW202122081A/zh unknown
- 2020-08-31 WO PCT/JP2020/032828 patent/WO2021040042A1/ja unknown
- 2020-08-31 JP JP2021543096A patent/JPWO2021040043A1/ja active Pending
-
2021
- 2021-05-27 JP JP2021088853A patent/JP2021121634A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007525214A (ja) * | 2004-01-30 | 2007-09-06 | ケムジェネックス・ファーマシューティカルズ・インコーポレイテッド | N−アセチルトランスフェラーゼ遺伝子型解析によって投与するナフタルイミド |
JP2007209286A (ja) * | 2006-02-10 | 2007-08-23 | Sutaagen:Kk | St合剤の副作用の危険性の判定方法 |
WO2008081537A1 (ja) | 2006-12-28 | 2008-07-10 | Human Cell Systems, Inc. | Lat1阻害活性を有する芳香族アミノ酸誘導体、それを含有するlat1阻害活性剤及びその製造方法 |
WO2017175827A1 (ja) * | 2016-04-08 | 2017-10-12 | 株式会社Cics | 合成アミノ酸の癌細胞内取り込みを保持する修飾法と正常細胞を保護する中性子捕捉療法 |
Non-Patent Citations (9)
Title |
---|
"NAT2*4'' allele means an SNP-free haplotype", PHARMACOGENOMICS, vol. 13, 2012, pages 31 - 41 |
DRUG METAB PHARMACOKINET, vol. 27, no. 1, 2012, pages 155 - 61 |
J RHEUMATOL, vol. 29, no. 12, 2002, pages 2492 - 2499 |
J. RHEUMATOL., vol. 29, no. 12, 2002 |
JUTABHA ET AL.: "89th Japan) Abstracts of the Annual Meeting of the Japanese Pharmacological Society", JOURNAL OF PHARMACOLOGICAL SCIENCES, vol. 130 |
JUTABHA ET AL.: "Abstracts of the 89th Annual Meeting of The Japanese Pharmacological Society", JOURNAL OF PHARMACOLOGICAL SCIENCES, vol. 130 |
MICHAEL F. WEMPE ET AL: "Metabolism and Pharmacokinetic Studies of JPH203, an L-Amino Acid Transporter 1 (LAT1) Selective Compound", DRUG METABOLISM AND PHARMACOKINETICS, JAPANESE SOCIETY FOR THE STUDY OF XENOBIOTICS (JSSX), TOKYO, JP, vol. 27, no. 1, 1 January 2012 (2012-01-01), JP, pages 155 - 161, XP055394226, ISSN: 1347-4367, DOI: 10.2133/dmpk.DMPK-11-RG-091 * |
ROTHEN, JEAN-PIERRE ET AL.: "Acetaminophen is an inhibitor of hepatic N- acetyltransferase 2 in vitro and in vivo", PHARMACOGENETICS, vol. 8, no. 6, 1 December 1998 (1998-12-01), pages 553 - 560, XP055796544, ISSN: 1462-2416 * |
See also references of EP4023298A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020073586A (ja) * | 2017-12-28 | 2020-05-14 | ジェイファーマ株式会社 | がん治療薬 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2021040043A1 (ja) | 2021-03-04 |
BR112022003220A2 (pt) | 2022-05-17 |
EP4023298A1 (en) | 2022-07-06 |
US20220288035A1 (en) | 2022-09-15 |
JP2021038214A (ja) | 2021-03-11 |
US20220288036A1 (en) | 2022-09-15 |
TW202122081A (zh) | 2021-06-16 |
CN114340621A (zh) | 2022-04-12 |
KR20220054603A (ko) | 2022-05-03 |
MX2022002312A (es) | 2022-06-02 |
CA3152367A1 (en) | 2021-03-04 |
MX2022002316A (es) | 2022-06-02 |
BR112022002894A2 (pt) | 2022-05-10 |
EP4023296A1 (en) | 2022-07-06 |
WO2021040043A1 (ja) | 2021-03-04 |
KR20220054312A (ko) | 2022-05-02 |
CN114364381A (zh) | 2022-04-15 |
TW202122080A (zh) | 2021-06-16 |
JP2021121634A (ja) | 2021-08-26 |
EP4023298A4 (en) | 2024-01-03 |
JP6894155B2 (ja) | 2021-06-23 |
CA3152369A1 (en) | 2021-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | The diversified function and potential therapy of ectopic olfactory receptors in non‐olfactory tissues | |
Bhandari et al. | Oxygen nanobubbles revert hypoxia by methylation programming | |
JP6533519B2 (ja) | Rasがんにおける脂質捕捉 | |
CN105636594A (zh) | 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物 | |
WO2021040042A1 (ja) | 特定の遺伝子マーカーを有する患者に用いるがん治療用の医薬組成物 | |
KR20160132496A (ko) | 초분자 조합 치료제 | |
CN105147613A (zh) | 增强药物递送和治疗剂有效性的方法 | |
Renziehausen et al. | Encapsulation of temozolomide in a calixarene nanocapsule improves its stability and enhances its therapeutic efficacy against glioblastoma | |
CN105008394A (zh) | 治疗结肠直肠癌的方法 | |
Xu et al. | Co-delivery of 5-fluorouracil and miRNA-34a mimics by host-guest self-assembly nanocarriers for efficacious targeted therapy in colorectal cancer patient-derived tumor xenografts | |
EP4035680A1 (en) | Therapy for diabetes using stem cell migration agent | |
Groer et al. | Intratumoral cancer chemotherapy with a carrier-based immunogenic cell-death eliciting platinum (IV) Agent | |
Wang et al. | PKM2 allosteric converter: a self-assembly peptide for suppressing renal cell carcinoma and sensitizing chemotherapy | |
CN109715790A (zh) | Crebbp相关的癌症疗法 | |
Zhou et al. | Drug repurposing in autosomal dominant polycystic kidney disease | |
Hong et al. | A HER2‐targeted Antibody‐Drug Conjugate, RC48‐ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer | |
Jiang et al. | Glycolysis regulation in tumor‐associated macrophages: Its role in tumor development and cancer treatment | |
KR20170070068A (ko) | 레트 증후군의 치료 | |
Nchienzia et al. | Hedgehog interacting protein (Hhip) regulates insulin secretion in mice fed high fat diets | |
Arab et al. | An overview of current therapeutic strategies for glioblastoma and the role of CD73 as an alternative curative approach | |
Andersen et al. | An α-fetoprotein-derived peptide reduces the uterine hyperplasia and increases the antitumour effect of tamoxifen | |
Zhao et al. | Mediated imaging and improved targeting of farnesylthiosalicylic acid delivery for pancreatic cancer via conjugation with near-infrared fluorescence heptamethine carbocyanine dye | |
JP2005530778A (ja) | 神経障害の予防および/または治療のための方法 | |
Han et al. | The combination of tetracyclines effectively ameliorates liver fibrosis via inhibition of EphB1/2 | |
Wang et al. | Gemcitabine nano-prodrug reprograms intratumoral metabolism and alleviates immunosuppression for hepatocellular carcinoma therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20856673 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3152367 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20227007268 Country of ref document: KR Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022003220 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2020856673 Country of ref document: EP Effective date: 20220330 |
|
ENP | Entry into the national phase |
Ref document number: 112022003220 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220221 |